SONIC HEALTHCARE LIMITED (SHL)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SHL

SHL - SONIC HEALTHCARE LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: 3.24
Index: ASX50 | ASX100 | ASX200 | ASX300 | ALL-ORDS

Sonic Healthcare is one of the world's largest medical diagnostics companies, providing laboratory and imaging services to medical practitioners, hospitals, community health services, and their collective patients. It was first listed in 1987.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$22.52

15 Sep
2025

-0.120

OPEN

$22.55

-0.53%

HIGH

$22.58

1,010,343

LOW

$22.38

TARGET
$28.304 25.7% upside
Franking for last dividend paid out: 35%
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . ALC . BMT . DOC . EBO . HLS . IDX . M7T . MDR . MPL . MVF . NHF . PSQ . RHC .
FNARENA'S MARKET CONSENSUS FORECASTS
SHL: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 107.0 120.9 xxx
DPS (cps) xxx 107.0 109.2 xxx
EPS Growth xxx - 0.4% 13.1% xxx
DPS Growth xxx 0.9% 2.1% xxx
PE Ratio xxx N/A 18.5 xxx
Dividend Yield xxx N/A 4.9% xxx
Div Pay Ratio(%) xxx 100.0% 90.3% xxx

Dividend yield today if purchased 3 years ago: 3.41%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 4.78

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages

Last ex-div: 04/09 - (franking ex-di

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx107.0
DPS All xxxxxxxxxxxxxxx107.0
Sales/Revenue xxxxxxxxxxxxxxx9,494.3 M
Book Value Per Share xxxxxxxxxxxxxxx1,733.3
Net Operating Cash Flow xxxxxxxxxxxxxxx1,296.8 M
Net Profit Margin xxxxxxxxxxxxxxx5.41 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx6.32 %
Return on Invested Capital xxxxxxxxxxxxxxx4.14 %
Return on Assets xxxxxxxxxxxxxxx3.27 %
Return on Equity xxxxxxxxxxxxxxx6.32 %
Return on Total Capital xxxxxxxxxxxxxxx5.95 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx446.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx461 M
Long Term Debt xxxxxxxxxxxxxxx4,710 M
Total Debt xxxxxxxxxxxxxxx5,171 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx674 M
Price To Book Value xxxxxxxxxxxxxxx1.55

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx462.7 M
Capex % of Sales xxxxxxxxxxxxxxx4.87 %
Cost of Goods Sold xxxxxxxxxxxxxxx7,072 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx1,642 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx231 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.2

No. Of Recommendations

7
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgan Stanley

xx/xx/xxxx

3

xxxxx-xxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Morgans

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

22/08/2025

3

Neutral

$25.20

11.90%

Sonic Healthcare delivered "decent" FY25 results, with profit up 7% year on year albeit -2% below Macquarie, driven by lower pathology revenue and margins.

The broker's FY26 earnings forecast sits -1% below the guidance midpoint. Group margins are forecast to fall -20bps to 17.7% due to the dilutive impacts of recent acquisitions.

While acknowledging potential synergy benefits from recent acquisitions, Macquarie notes margin headwinds and elevated leverage in the near term.

Further, commentary highlights risks remain around the US Protecting Access to Medicare Act, local Fair Work decision and full impacts from fee cuts.

Neutral retained, target falls to $25.20 from $25.50.

FORECAST
Macquarie forecasts a full year FY26 dividend of 107.00 cents and EPS of 107.00 cents.
Macquarie forecasts a full year FY27 dividend of 102.00 cents and EPS of 120.00 cents.

Citi

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

xx/xx/xxxx

4

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

UBS

xx/xx/xxxx

3

xxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Jarden

26/08/2025

3

Neutral

$27.92

23.98%

Jarden notes Sonic Healthcare's FY25 adjusted EBITDA missed the consensus by -2%, and net profit missed consensus by -3.8% and the broker's forecast by -2%.

The drivers of weakness included Cyclone Alfred impact in Australia in 2H, US impacted by West Division sale, payor loss and cyber disruption, and Germany hit by KV quota cuts.

FY26 EBITDA guidance was slightly weaker than expected, and at the net profit line was -8% below the broker's forecast on incremental D&A, interest and tax.

The broker trimmed FY26 EBITDA forecast by -1.5% and FY27 by -1.3%, with deeper cuts to net profit forecasts.

Neutral. Target cut to $27.92 from $29.84.

FORECAST
Jarden forecasts a full year FY26 dividend of 97.00 cents and EPS of 121.50 cents.
Jarden forecasts a full year FY27 dividend of 108.70 cents and EPS of 149.20 cents.
Access Extra Coverage Research History >

SHL STOCK CHART

FNArena News on SHL

1
Rudi’s View: US Equities, CSL, Macquarie Technology, Xero & More

Sep 11 2025 - Rudi's View
2
Rudi’s View: August Results; Standouts, Turnarounds, Failures & Misfits

Sep 10 2025 - Rudi's View
3
Australian Broker Call *Extra* Edition – Sep 03, 2025

Sep 03 2025 - Daily Market Reports
4
August In Review: Banks & Golds Drive Rally

Sep 03 2025 - Australia
5
Rudi’s View: A Glass Half-Full Outlook

Sep 03 2025 - Rudi's View

Latest Healthcare services News

1
Better Times Ahead For Sonic Healthcare?

Jun 20 2025 - Australia
2
The Significance Of Cosmetique’s ASX Listing

Feb 26 2025 - Small Caps
3
Building The No 3 Diagnostic Imaging Player

Jun 19 2024 - Small Caps
4
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
5
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
6
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
7
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
8
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
9
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
10
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps